Opportunities and Challenges in Antiparasitic Drug Discovery

@article{Pink2005OpportunitiesAC,
  title={Opportunities and Challenges in Antiparasitic Drug Discovery},
  author={R. Pink and Alan Hudson and Marie-Annick Mouri{\`e}s and Mary Margaret Bendig},
  journal={Nature Reviews Drug Discovery},
  year={2005},
  volume={4},
  pages={727-740}
}
New antiparasitic drugs are urgently needed to treat and control diseases such as malaria, leishmaniasis, sleeping sickness and filariasis, which affect millions of people each year. However, because the majority of those infected live in countries in which the prospects of any financial return on investment are too low to support market-driven drug discovery and development, alternative approaches are needed. In this article, challenges and opportunities for antiparasitic drug discovery are… Expand
Defining the targets of antiparasitic compounds.
TLDR
Methods currently used to identify the targets of antiparasitic compounds are described and discussed, which could circumvent this bottleneck and facilitate the development of new antiparAsitic drugs. Expand
Newer Antiparasitic Agents
TLDR
There is a need to change prescribing patterns of clinicians, promote research in anti-Parasitic drugs, and increase awareness of infection prevention and control in order to minimize the spread of parasitic diseases especially as newer anti-parasitic agents are scarce on the horizon. Expand
Antileishmanial Drugs: search for t SIR2 inhibitors
TLDR
An overview of the main strategies for antileishmanial drug development, mainly focused on the target-based drug development approach, is given. Expand
Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs.
TLDR
This work focuses on the potential drug targets that can be used for the treatment of leishmaniasis and brings to light how recent technological advances, such as structure-based drug design, structural genomics, and molecular dynamics, can beused to develop potent and affordable antileishmanial drugs. Expand
New chemotherapeutic strategies against malaria, leishmaniasis and trypanosomiases.
TLDR
This review deals with new drugs against Plasmodium, Leishmania and Trypanosoma parasites, focusing on the molecules that are in the most advanced stage of development. Expand
Recent Advances in the Discovery of Novel Antiprotozoal Agents
TLDR
This review has compiled the latest information on the structures and pharmacological activities of newly developed organic compounds against five major protozoan diseases, giardiasis, leishmaniasis, malaria, trichomoniasis, and trypanosomiasis, with the aim of showing recent advances in the discovery of new antiprotozoal drugs. Expand
Antitrypanosomal and antileishmanial activities
TLDR
The search for active compounds that provide the basis for the development of new therapies capable of generating curing against T. cruzi and Leishmania spp. Expand
Repurposing Drugs to Fight Hepatic Malaria Parasites
TLDR
Assessment of the anti-plasmodial activity of existing drugs, with an emphasis on the obligatory and clinically silent liver stage of infection, and the current knowledge on the classes of compounds that might be therapeutically relevant against Plasmodium in the context of other communicable diseases. Expand
Global phenotypic screening for antimalarials.
TLDR
This review describes the characterization of compounds inhibiting growth of the blood stages of Plasmodium falciparum, explores currently ongoing strategies to develop lead molecules, and endorse the concept of a "malaria box" of publicly accessible active compounds. Expand
Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates.
TLDR
Two complementary approaches have been pursued and a combination of both approaches to hopefully overcome some of the challenges of anti-trypanosomatid drug discovery has eventually been proposed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 120 REFERENCES
Medicines for Malaria Venture new developments in antimalarials.
TLDR
Malaria is a difficult problem but even if only a few of the potential drugs in the MMV pipeline become drugs, the control of malaria may again become possible. Expand
Antimalarial drug discovery: old and new approaches
  • P. Rosenthal
  • Biology, Medicine
  • Journal of Experimental Biology
  • 2003
TLDR
A number of new antimalarial therapies will likely be needed over the coming years, so it is important to pursue multiple strategies for drug discovery. Expand
Antimalarial drug discovery: efficacy models for compound screening
TLDR
Different in vitro and in vivo screens for antimalarial drug discovery are suggested and a streamlined process for evaluating new compounds on the path from drug discovery to development is recommended. Expand
New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis)
TLDR
In this review the patent literature for the period 1999 – 2002 was searched for claims of potential treatments for Chagas disease and 13 specific patents were identified and the majority of these patents dealt with inhibitors of cruzipain, a specific cysteine protease, which has been shown to be essential for the survival and growth of T. cruzi in its mammalian hosts. Expand
Specific chemotherapy of Chagas disease: controversies and advances.
TLDR
Promising approaches include interference with trypanothione synthesis and redox metabolism, in addition to inhibition of purine salvage, dihydrofolate reductase, phospholipid biosynthesis, and protein prenylation and acylation. Expand
RNAi-based discovery and validation of new drug targets in filarial nematodes.
TLDR
To identify and validate potential new drug targets, a collaborative research strategy utilizing bioinformatic filters and assessment of gene function by RNA interference in Caenorhabditis elegans and Brugia malayi is proposed. Expand
TUBERCULOSIS – STRATEGIES TOWARDS ANTI-INFECTIVES FOR A CHRONIC DISEASE
TLDR
Traditional drug discovery efforts have focused on killing actively growing Mycobacterium tuberculosis and can provide new agents for treating multi-drug-resistant strains, but are unlikely to significantly reduce disease mortality. Expand
Identification of an antimalarial synthetic trioxolane drug development candidate
TLDR
Here it is described how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project. Expand
The life and times of ivermectin — a success story
TLDR
The drug arose from a unique international collaboration between the public and private sectors, which incorporated the world's first and largest drug-donation programme and involved a unique association between governments, non-governmental organizations and industry. Expand
Antiparasitic properties of medicinal plants and other naturally occurring products.
TLDR
This chapter has drawn together a comprehensive list of medicinal plants and other natural products that have been shown to have activity against human and, to a lesser extent, animal parasites. Expand
...
1
2
3
4
5
...